Zacks Investment Research cut shares of Innovus Pharmaceuticals Inc (NASDAQ:INNV) from a buy rating to a hold rating in a research note released on Monday.
According to Zacks, “Innovus Pharmaceuticals, Inc. is a commercial-stage pharmaceutical company. It delivers non-prescription medicine and consumer care products to improve men’s and women’s health and vitality. It has a robust portfolio of sexual dysfunction treatments, cough, cold, respiratory disease treatments and pain management medication, as well as skin care products. Its male and female sexual health and vitality products include Zestra (R) to increase desire, arousal, and satisfaction in women; EjectDelay (R) for treating premature ejaculation; Sensum+ (TM) that increases penile sensitivity; Zestra Glide (R); and Vesele (R) to maximize nitric oxide beneficial effects on sexual functions and brain health. Innovus Pharmaceuticals, Inc. is based in San Diego, California. “
Innovus Pharmaceuticals (NASDAQ:INNV) opened at 0.2675 on Monday. The company’s 50-day moving average is $0.29 and its 200 day moving average is $0.26. Innovus Pharmaceuticals has a 12 month low of $0.03 and a 12 month high of $0.66. The firm’s market cap is $23.32 million.
About Innovus Pharmaceuticals
Innovus Pharmaceuticals, Inc is a pharmaceutical company engaged in the commercialization, licensing, and development of non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases. The Company markets approximately five products in the United States and six in a range of countries around the world through its commercial partners.